Sharifi S, Katamanin O, Jafferany M
Arch Dermatol Res. 2025; 317(1):427.
PMID: 39954108
DOI: 10.1007/s00403-025-03982-w.
Tu K, Jung C, Shih Y, Chang A
Front Immunol. 2024; 15:1403798.
PMID: 39136023
PMC: 11317294.
DOI: 10.3389/fimmu.2024.1403798.
Suswal K, Tomaszewski M, Romaniuk A, Swiechowska-Starek P, Zygmunt W, Styczen A
J Pers Med. 2024; 14(1).
PMID: 38276223
PMC: 10817474.
DOI: 10.3390/jpm14010008.
Docherty C, Denver N, Fisher S, Nilsen M, Hillyard D, Openshaw R
Mol Ther Nucleic Acids. 2020; 22:396-405.
PMID: 33230444
PMC: 7533346.
DOI: 10.1016/j.omtn.2020.09.002.
MacLean M
Pulm Circ. 2018; 8(2):2045894018759125.
PMID: 29468941
PMC: 5826007.
DOI: 10.1177/2045894018759125.
Hypothesis: Neuroendocrine Mechanisms (Hypothalamus-Growth Hormone-STAT5 Axis) Contribute to Sex Bias in Pulmonary Hypertension.
Sehgal P, Yang Y, Miller E
Mol Med. 2015; 21(1):688-701.
PMID: 26252185
PMC: 4749490.
DOI: 10.2119/molmed.2015.00122.
Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats.
Zhang E, Maruyama J, Yokochi A, Mitani Y, Sawada H, Nishikawa M
J Anesth. 2015; 29(5):715-23.
PMID: 25931318
DOI: 10.1007/s00540-015-2015-y.
A Sex-Specific MicroRNA-96/5-Hydroxytryptamine 1B Axis Influences Development of Pulmonary Hypertension.
Wallace E, Morrell N, Yang X, Long L, Stevens H, Nilsen M
Am J Respir Crit Care Med. 2015; 191(12):1432-42.
PMID: 25871906
PMC: 4476563.
DOI: 10.1164/rccm.201412-2148OC.
Transglutaminase 2-mediated serotonylation in pulmonary hypertension.
Penumatsa K, Fanburg B
Am J Physiol Lung Cell Mol Physiol. 2013; 306(4):L309-15.
PMID: 24375797
PMC: 3920225.
DOI: 10.1152/ajplung.00321.2013.
Serotonin and serotonin transport in the regulation of lactation.
Marshall A, Hernandez L, Horseman N
J Mammary Gland Biol Neoplasia. 2013; 19(1):139-46.
PMID: 24136337
DOI: 10.1007/s10911-013-9304-6.
Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms.
Friedman S, Andrus B
J Obes. 2012; 2012:505274.
PMID: 22988490
PMC: 3439985.
DOI: 10.1155/2012/505274.
Activation of the unfolded protein response is associated with pulmonary hypertension.
Yeager M, Reddy M, Nguyen C, Colvin K, Ivy D, Stenmark K
Pulm Circ. 2012; 2(2):229-40.
PMID: 22837864
PMC: 3401877.
DOI: 10.4103/2045-8932.97613.
Mechanisms involved in the regulation of bovine pulmonary vascular tone by the 5-HT1B receptor.
McKenzie C, Alapati V, Macdonald A, Shaw A
Br J Pharmacol. 2009; 159(1):188-200.
PMID: 19958363
PMC: 2823364.
DOI: 10.1111/j.1476-5381.2009.00519.x.
Fenfluramine disrupts the mitral valve interstitial cell response to serotonin.
Connolly J, Bakay M, Fulmer J, Gorman R, Gorman 3rd J, Oyama M
Am J Pathol. 2009; 175(3):988-97.
PMID: 19679875
PMC: 2731118.
DOI: 10.2353/ajpath.2009.081101.
Effects of streptozotocin-induced diabetes on the pharmacology of rat conduit and resistance intrapulmonary arteries.
Gurney A, Howarth F
Cardiovasc Diabetol. 2009; 8:4.
PMID: 19159454
PMC: 2632989.
DOI: 10.1186/1475-2840-8-4.
Pulmonary hypertension: therapeutic targets within the serotonin system.
Dempsie Y, MacLean M
Br J Pharmacol. 2008; 155(4):455-62.
PMID: 18536742
PMC: 2579665.
DOI: 10.1038/bjp.2008.241.
Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.
Villalon C, Centurion D
Naunyn Schmiedebergs Arch Pharmacol. 2007; 376(1-2):45-63.
PMID: 17703282
DOI: 10.1007/s00210-007-0179-1.
Serotonin induces pulmonary artery smooth muscle cell migration.
Day R, Agyeman A, Segel M, Chevere R, Angelosanto J, Suzuki Y
Biochem Pharmacol. 2005; 71(3):386-97.
PMID: 16316635
PMC: 1831537.
DOI: 10.1016/j.bcp.2005.10.035.
Reduced hypophagic effects of d-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice.
Lee M, Somerville E, Kennett G, Dourish C, Clifton P
Psychopharmacology (Berl). 2004; 176(1):39-49.
PMID: 15138762
DOI: 10.1007/s00213-004-1864-0.
5-HT moduline: an endogenous inhibitor of 5-HT(1B/1D)-mediated contraction in pulmonary arteries.
Murdoch R, Morecroft I, MacLean M
Br J Pharmacol. 2003; 138(5):795-800.
PMID: 12642380
PMC: 1573734.
DOI: 10.1038/sj.bjp.0705123.